Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.35 |
| ▸ | DAO | P14920 | 1/20 | 0.35 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.35 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.35 |
| ▸ | CLK1 | P49759 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | CTSA | P10619 | 1/20 | 0.33 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.33 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13263763 | 0.80 | CSNK1D (0.41) | KDM4ETDP1SIRT3CSNK1DCSNK1E | |
| Ammonia Solution, Strong SCHEMBL27811492 | 0.78 | CSNK1D (0.40) | HIPK2KDM4ETDP1CSNK1DCSNK1E | |
| SCHEMBL22045947 | 0.77 | CLK1 (0.42) | HIPK2KDM4ETDP1SIRT3CSNK1D | |
| SCHEMBL19044116 | 0.77 | CSNK1D (0.35) | HIPK2KDM4ETDP1SIRT3CSNK1D | |
| SCHEMBL3892453 | 0.77 | KDM4E (0.58) | KDM4EMAPKAPK2DAOCSNK1DCSNK1E | |
| SCHEMBL24925370 | 0.77 | DAO (0.36) | KDM4EMAPKAPK2DAOCSNK1DCSNK1E | |
| SCHEMBL24249186 | 0.77 | RPS6KA3 (0.42) | KDM4EMAPKAPK2DAOCSNK1DCSNK1E | |
| SCHEMBL255425 | 0.74 | CLK1 (0.48) | KDM4EMAPKAPK2DAOCSNK1DCSNK1E | |
| SCHEMBL906750 | 0.74 | ALDH1A1 (0.59) | KDM4ETDP1MAPT | |
| SCHEMBL25370522 | 0.73 | KDM4E (0.36) | KDM4EMAPKAPK2DAOCSNK1DCSNK1E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230020922-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-01-19 | — | — | US | disclosed |
| EP-0134535-B1 | 1,6-NAPHTHYRIDIN DERIVATIVES USEFUL AS CARDIOTONICS AND PREPARATION THEREOF | STERLING DRUG INC. (US) | 1988-10-26 | — | — | EP | disclosed |
| EP-0101952-B1 | 5-ALKYL-1,6-NAPHTHYRIDIN-2(1H)-ONES, INTERMEDIATES, THEIR PREPARATION AND THEIR CARDIOTONIC USE | STERLING DRUG INC. (US) | 1987-09-23 | — | — | EP | disclosed |
| EP-0204335-A2 | 2(1H)-Pyridin-ones useful as intermediates | STERLING DRUG INC. (US) | 1986-12-10 | — | — | EP | disclosed |
| US-4604399-A | 5-methyl(or ethyl)-1,6-naphthyridin-2(1H)-one 6-oxides, their preparation and the cardiotonic use thereof | STERLING DRUG INC. (US) | 1986-08-05 | — | — | US | disclosed |
| US-4559347-A | 3-Substituted-5-alkyl-1,6-naphthyridin-2(1H)-ones, cardiotonic use and preparation thereof | STERLING DRUG INC. (US) | 1985-12-17 | — | — | US | disclosed |
| US-4532247-A | Increases cardiac contractility | STERLING DRUG INC. (US) | 1985-07-30 | — | — | US | disclosed |
| US-4517190-A | 5-Alkyl-1,6-naphthyridin-2(1H)-ones and cardiotonic use thereof | STERLING DRUG INC. (US) | 1985-05-14 | — | — | US | disclosed |
| EP-0134535-A1 | 1,6-Naphthyridin derivatives useful as cardiotonics and preparation thereof | STERLING DRUG INC. (US) | 1985-03-20 | — | — | EP | disclosed |
| EP-0101952-A1 | 5-Alkyl-1,6-naphthyridin-2(1H)-ones, intermediates, their preparation and their cardiotonic use | STERLING DRUG INC. (US) | 1984-03-07 | — | — | EP | disclosed |
| US-4415580-A | Certain 2-(1H)-pyridinones cardiotonic compositions containing same and method of using same | STERLING DRUG INC. (US) | 1983-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230020922-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SNRPA1 | HIPK2 620/4885KDM4E 2530/4885MAPKAPK2 2911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.